Nephroprotective Plant Species Used in Brazilian Traditional Medicine for Renal Diseases: Ethnomedical, Pharmacological, and Chemical Insights

被引：0

作者：

Carlesso, Rodrigo Moraes ^{[1
]}

Cappellari, Yasmin Louise Ramos ^{[1
,2
]}

Boeff, Daiana Daniele ^{[1
,2
]}

Pereira, Alicia da Costa ^{[1
]}

Rusch, Elisa Schmitt ^{[1
]}

Claudino, Thiago de Souza ^{[3
]}

Ritter, Mara Rejane ^{[4
]}

Konrath, Eduardo Luis ^{[1
,2
]}

机构：

[1] Univ Fed Rio Grande Sul UFRGS, Fac Pharm, Lab Pharmacognosy, BR-90010150 Porto Alegre, Brazil

[2] Univ Fed Rio Grande Sul PPGCF UFRGS, Fac Pharm, Posgrad Program Pharmaceut Sci, BR-90010150 Porto Alegre, Brazil

[3] Fed Inst Educ Sci & Technol Parana IFPR, Irati Campus, BR-84500000 Irati Campus, Brazil

[4] Univ Fed Rio Grande Sul UFRGS, Biosci Inst, Dept Bot, BR-90010150 Porto Alegre, Brazil

来源：

PLANTS-BASEL | 2025年 / 14卷 / 05期

关键词：

nephroprotection; kidney disorders; ethnomedicine; secondary metabolites; plant extracts; CHRONIC KIDNEY-DISEASE; GENTAMICIN-INDUCED NEPHROTOXICITY; BREDEMEYERA-FLORIBUNDA WILLD; PHYLLANTHUS-NIRURI; AQUEOUS EXTRACT; OXIDATIVE STRESS; ETHANOL EXTRACT; DIURETIC ACTIVITY; CRUDE EXTRACT; INJURY;

D O I：

10.3390/plants14050648

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

The prevalence of kidney-related diseases has been increasing and has emerged globally as a leading cause of mortality, especially in developing countries where they are considered a neglected public health problem. Renal diseases are commonly progressive and may cause irreversible loss of organ function, eventually necessitating renal replacement therapy. Although different pharmaceuticals are considered for the treatment of these pathologies, the uncertain effectiveness and presence of adverse effects have generated a growing need for the development of novel nephroprotective compounds. Because many medicinal herbs are typically used in Brazilian folk medicine to prevent and cure kidney ailments, ethnomedicine may play a promising and strategic role in identifying and adding new potential molecules to the pharmacological arsenal. This review focuses on the use of plants and secondary metabolites belonging to different classes to treat renal diseases, associating the screened plant extracts with the bioactive components present in each species. Flavonoids and triterpenes are notable metabolites that have therapeutic potential. The putative pharmacological mechanisms related to nephroprotective properties are also discussed in in vitro and in vivo models, when available.

引用

页数：42

共 153 条

[11] Langenberg C., Bagshaw S.M., May C.N., Bellomo R., The histopathology of septic acute kidney injury: A systematic review, Crit. Care, 12, (2008)
[12] Levey A.S., Coresh J., Chronic kidney disease, Lancet, 379, pp. 165-180, (2012)
[13] Dwyer J.P., Parving H.H., Hunsicker L.G., Ravid M., Remuzzi G., Lewis J.B., Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: Results from the DEMAND study, Cardiorenal Med, 2, pp. 1-10, (2012)
[14] Kelly J.T., Su G., Zhang L., Qin X., Marshall S., Gonzalez-Ortiz A., Clase C.M., Campbell K.L., Xu H., Carrero J.J., Modifiable lifestyle factors for primary prevention of CKD: A systematic review and meta-analysis, J. Am. Soc. Nephrol, 32, pp. 239-253, (2021)
[15] Palmer S.C., Maggo J.K., Campbell K.L., Craig J.C., Johnson D.W., Sutanto B., Ruospo M., Tong A., Strippoli G.F., Dietary interventions for adults with chronic kidney disease, Cochrane Database Syst. Rev, 4, (2017)
[16] Kalantar-Zadeh K., Jafar T.H., Nitsch D., Neuen B.L., Perkovic V., Chronic kidney disease, Lancet, 398, pp. 786-802, (2021)
[17] Yanai H., Adachi H., Hakoshima M., Katsuyama H., Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease, Int. J. Mol. Sci, 22, (2021)
[18] Barrera-Chimal J., Girerd S., Jaisser F., Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis, Kidney Int, 96, pp. 302-319, (2019)
[19] Fried L.F., Emanuele N., Zhang J.H., Brophy M., Conner T.A., Duckworth W., Leehey D.J., McCullough P.A., O'Connor T., Palevsky P.M., Et al., Combined angiotensin inhibition for the treatment of diabetic nephropathy, N. Engl. J. Med, 369, pp. 1892-1903, (2013)
[20] Mende C.W., Chronic kidney disease and SGLT2 inhibitors: A review of the evolving treatment landscape, Adv. Ther, 39, pp. 148-164, (2022)

← 1 2 3 4 5 6 7 8 9 10 →